Literature DB >> 29771508

Comparison of Kinetics, Toxicity, Oligomer Formation, and Membrane Binding Capacity of α-Synuclein Familial Mutations at the A53 Site, Including the Newly Discovered A53V Mutation.

Ganesh M Mohite1, Rakesh Kumar1, Rajlaxmi Panigrahi1, Ambuja Navalkar1, Nitu Singh1, Debalina Datta1, Surabhi Mehra1, Soumik Ray1, Laxmikant G Gadhe1, Subhadeep Das1, Namrata Singh1, Debdeep Chatterjee1, Ashutosh Kumar1, Samir K Maji1.   

Abstract

The involvement of α-synuclein (α-Syn) amyloid formation in Parkinson's disease (PD) pathogenesis is supported by the discovery of α-Syn gene (SNCA) mutations linked with familial PD, which are known to modulate the oligomerization and aggregation of α-Syn. Recently, the A53V mutation has been discovered, which leads to late-onset PD. In this study, we characterized for the first time the biophysical properties of A53V, including the aggregation propensities, toxicity of aggregated species, and membrane binding capability, along with those of all familial mutations at the A53 position. Our data suggest that the A53V mutation accelerates fibrillation of α-Syn without affecting the overall morphology or cytotoxicity of fibrils compared to those of the wild-type (WT) protein. The aggregation propensity for A53 mutants is found to decrease in the following order: A53T > A53V > WT > A53E. In addition, a time course aggregation study reveals that the A53V mutant promotes early oligomerization similar to the case for the A53T mutation. It promotes the largest amount of oligomer formation immediately after dissolution, which is cytotoxic. Although in the presence of membrane-mimicking environments, the A53V mutation showed an extent of helix induction capacity similar to that of the WT protein, it exhibited less binding to lipid vesicles. The nuclear magnetic resonance study revealed unique chemical shift perturbations caused by the A53V mutation compared to those caused by other mutations at the A53 site. This study might help to establish the disease-causing mechanism of A53V in PD pathology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29771508     DOI: 10.1021/acs.biochem.8b00314

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease.

Authors:  Anwesha Sanyal; Sayan Dutta; Ali Camara; Aswathy Chandran; Antonius Koller; Ben G Watson; Ranjan Sengupta; Daniel Ysselstein; Paola Montenegro; Jason Cannon; Jean-Christophe Rochet; Seema Mattoo
Journal:  J Mol Biol       Date:  2019-04-27       Impact factor: 5.469

Review 2.  Consequences of variability in α-synuclein fibril structure on strain biology.

Authors:  Sara A M Holec; Samantha L Liu; Amanda L Woerman
Journal:  Acta Neuropathol       Date:  2022-02-04       Impact factor: 17.088

3.  Triphala inhibits alpha-synuclein fibrillization and their interaction study by NMR provides insights into the self-association of the protein.

Authors:  Mandar Bopardikar; Anusri Bhattacharya; Veera Mohana Rao Kakita; Kavitha Rachineni; Lalit C Borde; Sinjan Choudhary; Sri Rama Koti Ainavarapu; Ramakrishna V Hosur
Journal:  RSC Adv       Date:  2019-09-10       Impact factor: 4.036

4.  Genetic Analysis of Patients With Early-Onset Parkinson's Disease in Eastern China.

Authors:  Ping Hua; Yuwen Zhao; Qian Zeng; Lanting Li; Jingru Ren; Jifeng Guo; Beisha Tang; Weiguo Liu
Journal:  Front Aging Neurosci       Date:  2022-05-11       Impact factor: 5.702

5.  Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy.

Authors:  Nguyen-Vi Mohamed; Julien Sirois; Janani Ramamurthy; Meghna Mathur; Paula Lépine; Eric Deneault; Gilles Maussion; Michael Nicouleau; Carol X-Q Chen; Narges Abdian; Vincent Soubannier; Eddie Cai; Harris Nami; Rhalena A Thomas; Dingke Wen; Mahdieh Tabatabaei; Lenore K Beitel; Karamjit Singh Dolt; Jason Karamchandani; Jo Anne Stratton; Tilo Kunath; Edward A Fon; Thomas M Durcan
Journal:  Brain Commun       Date:  2021-09-25

Review 6.  Structural and Functional Insights into α-Synuclein Fibril Polymorphism.

Authors:  Surabhi Mehra; Laxmikant Gadhe; Riya Bera; Ajay Singh Sawner; Samir K Maji
Journal:  Biomolecules       Date:  2021-09-28

Review 7.  Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43.

Authors:  Airi Tarutani; Tadashi Adachi; Hiroyasu Akatsu; Yoshio Hashizume; Kazuko Hasegawa; Yuko Saito; Andrew C Robinson; David M A Mann; Mari Yoshida; Shigeo Murayama; Masato Hasegawa
Journal:  Acta Neuropathol       Date:  2022-05-05       Impact factor: 15.887

8.  Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein.

Authors:  Sabine M Ulamec; Roberto Maya-Martinez; Emily J Byrd; Katherine M Dewison; Yong Xu; Leon F Willis; Frank Sobott; George R Heath; Patricija van Oosten Hawle; Vladimir L Buchman; Sheena E Radford; David J Brockwell
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

Review 9.  Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease.

Authors:  Joanna A Motyl; Joanna B Strosznajder; Agnieszka Wencel; Robert P Strosznajder
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

10.  Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors.

Authors:  Anthony R Braun; Elly E Liao; Mian Horvath; Prakriti Kalra; Karen Acosta; Malaney C Young; Noah Nathan Kochen; Chih Hung Lo; Roland Brown; Michael D Evans; William C K Pomerantz; Elizabeth Rhoades; Kelvin Luk; Razvan L Cornea; David D Thomas; Jonathan N Sachs
Journal:  NPJ Parkinsons Dis       Date:  2021-06-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.